Get the Stockscreener App
7.205
1.09%
-0.115
Agenus Inc stock is traded at $7.205, with a volume of 623.83K.
It is down -1.09% in the last 24 hours and up +44.51% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$7.32
Open:
$7.3
24h Volume:
623.83K
Relative Volume:
0.16
Market Cap:
$324.07M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
4.3157
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
+3.43%
1M Performance:
+44.51%
6M Performance:
+137.38%
1Y Performance:
+56.37%
1-Day Range:
$6.9601
$7.305
1-Week Range:
$6.42
$7.46
52-Week Range:
$2.71
$8.85
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
7.20 | 329.47M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
515.76 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.65 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.87 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.83 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus Inc.AGEN Stock Chart Technical Analysis For 05-07-18 Monday Night Raw (hiEG5bsL6M) - Mshale
AGENUS INC SEC Filing (Aug 17, 2026) - Stock Titan
Agenus Puts Its BOT+BAL Cancer Combo To The Test - Finimize
Renaissance Technologies LLC Sells 257,900 Shares of Agenus Inc. $AGEN - MarketBeat
HC Wainwright Estimates Agenus' Q3 Earnings (NASDAQ:AGEN) - MarketBeat
Bold Move By Agenus: Cutting Costs By 60% To Focus On Groundbreaking Cancer Treatments Nikoloz Basilashvili (41VwNJliWR) - Mshale
Agenus (NASDAQ: AGEN) awards 1.97M performance-tied stock options to CEO - Stock Titan
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL S - The National Law Review
Form 8K Agenus Inc For: 11 August By Investing.com - Investing.com South Africa
Agenus appoints Marco Tullio Marcucci to board of directors By Investing.com - Investing.com Nigeria
Agenus appoints Marco Tullio Marcucci to board of directors - Investing.com
Agenus Director Brian Corvese Granted 100,000 Stock Options Under 2019 Equity Incentive Plan - Kalkine Media
Agenus Director Thomas L. Harrison Granted 50,000 Stock Options Under 2019 Equity Incentive Plan - Kalkine Media
AGENUS appoints Marco Tullio Marcucci to its Board as Class II director - TradingView
Agenus Inc. (AGEN) expands board, appoints Marco Tullio Marcucci as Class II director - Stock Titan
Agenus Inc (AGEN) awards 50,000 stock options to director Thomas L. Harrison - Stock Titan
Agenus (AGEN) director Brian Corvese receives 100,000 stock options at $7.78 - Stock Titan
Wainwright cuts Agenus stock price target to $25 on higher costs - Investing.com Nigeria
Wainwright cuts Agenus stock price target to $25 on higher costs By Investing.com - Investing.com India
HC Wainwright Issues Positive Outlook for Agenus Earnings - MarketBeat
AGEN Stock (Agenus Stock) AGEN STOCK Analysis AGEN STOCK PREDICTION In AGEN Stock News Today Bella Vaughn Hunter Johnson Engagement (u90ZBraz9y) - Mshale
Why Agenus (AGEN Stock) Just Rocketed Up—Buy Now Or Too Late? Cigarette (l3DDhgoK4D) - Mshale
Agenus Inc (AGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agenus (AGEN) Stock Drops As One Off Gain Masks Profit Slip - Sahm
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Agenus Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Agenus Files for Resale of Up to 78 Million Shares - marketscreener.com
Agenus: Q2 Earnings Snapshot - Yahoo Finance
AGENUS INC Q2 2026: Revenue $34.5M, EPS $0.96— 10-Q Summary - TradingView
Agenus (NASDAQ: AGEN) raises $85M and books Zydus gain but flags going concern risk - Stock Titan
Agenus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Agenus (NASDAQ: AGEN) files S-3 for 77.9M share resale and warrant cash - Stock Titan
Agenus Inc. (AGEN) awards 50,000 stock options to director Wright - Stock Titan
AGENUS INC (AGEN) awards 100,000 stock options to its CMO - Stock Titan
Agenus Inc (AGEN) Stock News Today - TradingKey
Agenus Inc. (AGEN) grants director 50,000 stock options at $7.78 - Stock Titan
Agenus (AGEN) awards 200,000 stock options to executive chair Jennifer Buell - Stock Titan
Agenus Advances BOT+BAL in Neoadjuvant MSS Colon Cancer Through Phase 3 ROBBIN Trial - Oncodaily
Agenus reports Q2 results, plans phase 3 colon cancer trial - Investing.com
Agenus reports Q2 results, plans phase 3 colon cancer trial By Investing.com - Investing.com Nigeria
Is Agenus Inc (AGEN) Overvalued After Q2 Earnings Beat? Q2 EPS: $0.06, Revenue: $34.5M; GF Score: 40/100 - GuruFocus
Form 8K Agenus Inc For: 6 August By Investing.com - Investing.com Canada
Agenus reports $34.5 million second quarter revenue as ROBBIN trial advances - Quiver Quantitative
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer - Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - TMX Newsfile
Agenus Inc expected to post earnings of 5 cents a shareEarnings Preview - TradingView
AGEN|Agenus Inc|Price:7.810|Chg%:+0.310 - TradingKey
Agenus (AGEN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
AGENUS INC SEC Filing (Jul 28, 2026) - Stock Titan
Agenus (NASDAQ:AGEN) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
BlackRock (AGEN) discloses 2.51M-share, 6% stake in Agenus common stock - Stock Titan
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):